Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILCAAT: IL-2 + ART in HIV
NCT00013611Phase 3Completed
- Sponsor
- University of Minnesota
- Start
- Mar 2001
- Primary completion
- Jan 2007
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aldesleukin in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Minnesota. Primary endpoint: New or Recurrent Disease Progression Events or Death. Started Mar 2001; status: completed.
02
Drugs
aldesleukin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00013611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00013611.